FULL EVENT GUIDE
Get Your Copy of the Full Event Guide Now:
*Having trouble downloading the brochure? Let us know and we’ll email it to you instead.
Catch the Latest Clinical Data from Leading Hippo Companies:
Journey of VT3989: Clinical Insights & Overcoming Challenges
Neelesh Sharma, Chief Medical Officer, Vivace Therapeutics
Presenting a Novel Pan TEAD Inhibitor to Treat Hippo Pathway Dysregulated Tumors
Michelle Chen, Chief Business Officer, Insilico Medicine
Discovery & Development of a Novel Covalent TEAD Inhibitor with Exceptional Anti-Cancer Activity & Druggability
Shirley Guo, Director of Biology, BridGene Biosciences